Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial

October 7, 2019

Nolasiban

Humberstone A., Terrill P., Macgregor L., Loumaye E. ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA Fertility…

Read more

Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment

Linzagolix

Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E. ASRM 2019 Scientific Congress…

Read more

The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial

May 20, 2019

Linzagolix

Elke Bestel, Andrew Humberstone, Veronique Lecomte, Ernest Loumaye, Jean-Pierre Gotteland, James A. Simon ACOG Annual Conference, 03-06 May 2019, Nashville,…

Read more

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

April 8, 2019

Nolasiban

Sung Hye Kim, Lucia Riaposova, Hauwa Ahmed, Oliver Pohl, André Chollet, Jean-Pierre Gotteland, Aylin Hanyaloglu, Phillip R. Bennett & Vasso…

Read more

Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

March 25, 2019

OBE022

Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone Oliver…

Read more

Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor

March 18, 2019

OBE022

Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye SRI…

Read more

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

January 28, 2019

OBE022

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg…

Read more

A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer

October 9, 2018

Nolasiban

Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E. ASRM 2018, 6-10 October 2018, Denver, CO

Read more

Effects of the oral oxytocin receptor antagonist nolasiban on early embryonic development

July 4, 2018

Nolasiban

O. Pohl, D. Perks, R. Sisti, J.P. GottelandESHRE Annual Conference, 01-04 July 2018, Barcelona, Spain

Read more

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor

May 18, 2018

OBE022

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm…

Read more